Answers are grounded in this paper and cite their sources.
A review of recruitment characteristics of StarMS (ISRCTN88667898), the first clinical trial to randomise patients with treatment naïve rapidly evolving severe Multiple Sclerosis (RES-MS), or active relapsing remitting MS (RRMS) despite disease modifying treatment (DMT), to autologous haematopoietic stem cell transplantation (aHSCT) or high efficacy DMTs.
No takes yet. Share an insight, caveat, or question.
Brittain et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: